Loading…
DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model
Aims To explore the cost-effectiveness of alternative methods of screening family members for hypertrophic cardiomyopathy (HCM), the most common monogenic cardiac disorder and the most frequent cause of sudden cardiac death (SCD) in young people. Methods and results Economic decision model comparing...
Saved in:
Published in: | European heart journal 2010-04, Vol.31 (8), p.926-935 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c474t-9919a39244060bdd7f1cf3e23f82b86c1aa0f590add78387858246902477d1ef3 |
---|---|
cites | cdi_FETCH-LOGICAL-c474t-9919a39244060bdd7f1cf3e23f82b86c1aa0f590add78387858246902477d1ef3 |
container_end_page | 935 |
container_issue | 8 |
container_start_page | 926 |
container_title | European heart journal |
container_volume | 31 |
creator | Wordsworth, Sarah Leal, José Blair, Edward Legood, Rosa Thomson, Kate Seller, Anneke Taylor, Jenny Watkins, Hugh |
description | Aims To explore the cost-effectiveness of alternative methods of screening family members for hypertrophic cardiomyopathy (HCM), the most common monogenic cardiac disorder and the most frequent cause of sudden cardiac death (SCD) in young people. Methods and results Economic decision model comparing cascade screening by genetic, as opposed to clinical methods. The incremental cost per life year saved was €14 397 for the cascade genetic compared with the cascade clinical approach. Genetic diagnostic strategies are more likely to be cost-effective than clinical tests alone. The costs for cascade molecular genetic testing were slightly higher than clinical testing in the short run, but this was largely because the genetic approach is more effective and identifies more individuals at risk. Conclusion The use of molecular genetic information in the diagnosis and management of HCM is a cost-effective approach to the primary prevention of SCD in these patients. |
doi_str_mv | 10.1093/eurheartj/ehq067 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733887424</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733887424</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-9919a39244060bdd7f1cf3e23f82b86c1aa0f590add78387858246902477d1ef3</originalsourceid><addsrcrecordid>eNpFkE1v1DAQhi0EotvCnRPKBXEKHX_EH9yqlm6BFUgViIqL5XXGJCVZp7YXsf-eoF2W0xzmed8ZPYS8oPCGguHnuE0dulTuz7F7AKkekQVtGKuNFM1jsgBqmlpKfXdCTnO-BwAtqXxKThgwY3gDC7K8-nRRFcyl3_yoQkxVt5swlRSnrveVd6nt47iLkyvd7m3lKh9zqTEE9KX_hRvMuRpji8Mz8iS4IePzwzwjX6_ffbm8qVefl-8vL1a1F0qU2hhqHDdMCJCwblsVqA8cGQ-arbX01DkIjQE3rzTXSjeaCWmACaVaioGfkdf73inFh-38tx377HEY3AbjNlvFudZKMDGTsCd9ijknDHZK_ejSzlKwf-3Zoz27tzdHXh7Kt-sR22Pgn64ZeHUAXPZuCMltfJ__c0wCB0Znrt5zfS74-7h36aedz6jG3tx9t6uPt7dL0XyzH_gfa5eKhA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733887424</pqid></control><display><type>article</type><title>DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model</title><source>Oxford Journals Online</source><creator>Wordsworth, Sarah ; Leal, José ; Blair, Edward ; Legood, Rosa ; Thomson, Kate ; Seller, Anneke ; Taylor, Jenny ; Watkins, Hugh</creator><creatorcontrib>Wordsworth, Sarah ; Leal, José ; Blair, Edward ; Legood, Rosa ; Thomson, Kate ; Seller, Anneke ; Taylor, Jenny ; Watkins, Hugh</creatorcontrib><description>Aims To explore the cost-effectiveness of alternative methods of screening family members for hypertrophic cardiomyopathy (HCM), the most common monogenic cardiac disorder and the most frequent cause of sudden cardiac death (SCD) in young people. Methods and results Economic decision model comparing cascade screening by genetic, as opposed to clinical methods. The incremental cost per life year saved was €14 397 for the cascade genetic compared with the cascade clinical approach. Genetic diagnostic strategies are more likely to be cost-effective than clinical tests alone. The costs for cascade molecular genetic testing were slightly higher than clinical testing in the short run, but this was largely because the genetic approach is more effective and identifies more individuals at risk. Conclusion The use of molecular genetic information in the diagnosis and management of HCM is a cost-effective approach to the primary prevention of SCD in these patients.</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/eurheartj/ehq067</identifier><identifier>PMID: 20299350</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adolescent ; Adult ; Aged ; Biological and medical sciences ; Cardiology. Vascular system ; Cardiomyopathy, Hypertrophic, Familial - diagnosis ; Cardiomyopathy, Hypertrophic, Familial - economics ; Cardiomyopathy, Hypertrophic, Familial - genetics ; Child ; Cost-Benefit Analysis ; Cost-effectiveness analysis ; Death, Sudden, Cardiac - prevention & control ; Decision Trees ; Forecasting ; Genetic Testing - economics ; Genetic Testing - standards ; Genetics ; Heart ; Humans ; Hypertrophic cardiomyopathy ; Medical sciences ; Middle Aged ; Models, Economic ; Myocarditis. Cardiomyopathies ; Pedigree ; Risk Assessment ; Sensitivity and Specificity ; Young Adult</subject><ispartof>European heart journal, 2010-04, Vol.31 (8), p.926-935</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-9919a39244060bdd7f1cf3e23f82b86c1aa0f590add78387858246902477d1ef3</citedby><cites>FETCH-LOGICAL-c474t-9919a39244060bdd7f1cf3e23f82b86c1aa0f590add78387858246902477d1ef3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22603021$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20299350$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wordsworth, Sarah</creatorcontrib><creatorcontrib>Leal, José</creatorcontrib><creatorcontrib>Blair, Edward</creatorcontrib><creatorcontrib>Legood, Rosa</creatorcontrib><creatorcontrib>Thomson, Kate</creatorcontrib><creatorcontrib>Seller, Anneke</creatorcontrib><creatorcontrib>Taylor, Jenny</creatorcontrib><creatorcontrib>Watkins, Hugh</creatorcontrib><title>DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model</title><title>European heart journal</title><addtitle>Eur Heart J</addtitle><description>Aims To explore the cost-effectiveness of alternative methods of screening family members for hypertrophic cardiomyopathy (HCM), the most common monogenic cardiac disorder and the most frequent cause of sudden cardiac death (SCD) in young people. Methods and results Economic decision model comparing cascade screening by genetic, as opposed to clinical methods. The incremental cost per life year saved was €14 397 for the cascade genetic compared with the cascade clinical approach. Genetic diagnostic strategies are more likely to be cost-effective than clinical tests alone. The costs for cascade molecular genetic testing were slightly higher than clinical testing in the short run, but this was largely because the genetic approach is more effective and identifies more individuals at risk. Conclusion The use of molecular genetic information in the diagnosis and management of HCM is a cost-effective approach to the primary prevention of SCD in these patients.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Cardiomyopathy, Hypertrophic, Familial - diagnosis</subject><subject>Cardiomyopathy, Hypertrophic, Familial - economics</subject><subject>Cardiomyopathy, Hypertrophic, Familial - genetics</subject><subject>Child</subject><subject>Cost-Benefit Analysis</subject><subject>Cost-effectiveness analysis</subject><subject>Death, Sudden, Cardiac - prevention & control</subject><subject>Decision Trees</subject><subject>Forecasting</subject><subject>Genetic Testing - economics</subject><subject>Genetic Testing - standards</subject><subject>Genetics</subject><subject>Heart</subject><subject>Humans</subject><subject>Hypertrophic cardiomyopathy</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Models, Economic</subject><subject>Myocarditis. Cardiomyopathies</subject><subject>Pedigree</subject><subject>Risk Assessment</subject><subject>Sensitivity and Specificity</subject><subject>Young Adult</subject><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNpFkE1v1DAQhi0EotvCnRPKBXEKHX_EH9yqlm6BFUgViIqL5XXGJCVZp7YXsf-eoF2W0xzmed8ZPYS8oPCGguHnuE0dulTuz7F7AKkekQVtGKuNFM1jsgBqmlpKfXdCTnO-BwAtqXxKThgwY3gDC7K8-nRRFcyl3_yoQkxVt5swlRSnrveVd6nt47iLkyvd7m3lKh9zqTEE9KX_hRvMuRpji8Mz8iS4IePzwzwjX6_ffbm8qVefl-8vL1a1F0qU2hhqHDdMCJCwblsVqA8cGQ-arbX01DkIjQE3rzTXSjeaCWmACaVaioGfkdf73inFh-38tx377HEY3AbjNlvFudZKMDGTsCd9ijknDHZK_ejSzlKwf-3Zoz27tzdHXh7Kt-sR22Pgn64ZeHUAXPZuCMltfJ__c0wCB0Znrt5zfS74-7h36aedz6jG3tx9t6uPt7dL0XyzH_gfa5eKhA</recordid><startdate>20100401</startdate><enddate>20100401</enddate><creator>Wordsworth, Sarah</creator><creator>Leal, José</creator><creator>Blair, Edward</creator><creator>Legood, Rosa</creator><creator>Thomson, Kate</creator><creator>Seller, Anneke</creator><creator>Taylor, Jenny</creator><creator>Watkins, Hugh</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100401</creationdate><title>DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model</title><author>Wordsworth, Sarah ; Leal, José ; Blair, Edward ; Legood, Rosa ; Thomson, Kate ; Seller, Anneke ; Taylor, Jenny ; Watkins, Hugh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-9919a39244060bdd7f1cf3e23f82b86c1aa0f590add78387858246902477d1ef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Cardiomyopathy, Hypertrophic, Familial - diagnosis</topic><topic>Cardiomyopathy, Hypertrophic, Familial - economics</topic><topic>Cardiomyopathy, Hypertrophic, Familial - genetics</topic><topic>Child</topic><topic>Cost-Benefit Analysis</topic><topic>Cost-effectiveness analysis</topic><topic>Death, Sudden, Cardiac - prevention & control</topic><topic>Decision Trees</topic><topic>Forecasting</topic><topic>Genetic Testing - economics</topic><topic>Genetic Testing - standards</topic><topic>Genetics</topic><topic>Heart</topic><topic>Humans</topic><topic>Hypertrophic cardiomyopathy</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Models, Economic</topic><topic>Myocarditis. Cardiomyopathies</topic><topic>Pedigree</topic><topic>Risk Assessment</topic><topic>Sensitivity and Specificity</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wordsworth, Sarah</creatorcontrib><creatorcontrib>Leal, José</creatorcontrib><creatorcontrib>Blair, Edward</creatorcontrib><creatorcontrib>Legood, Rosa</creatorcontrib><creatorcontrib>Thomson, Kate</creatorcontrib><creatorcontrib>Seller, Anneke</creatorcontrib><creatorcontrib>Taylor, Jenny</creatorcontrib><creatorcontrib>Watkins, Hugh</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wordsworth, Sarah</au><au>Leal, José</au><au>Blair, Edward</au><au>Legood, Rosa</au><au>Thomson, Kate</au><au>Seller, Anneke</au><au>Taylor, Jenny</au><au>Watkins, Hugh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model</atitle><jtitle>European heart journal</jtitle><addtitle>Eur Heart J</addtitle><date>2010-04-01</date><risdate>2010</risdate><volume>31</volume><issue>8</issue><spage>926</spage><epage>935</epage><pages>926-935</pages><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>Aims To explore the cost-effectiveness of alternative methods of screening family members for hypertrophic cardiomyopathy (HCM), the most common monogenic cardiac disorder and the most frequent cause of sudden cardiac death (SCD) in young people. Methods and results Economic decision model comparing cascade screening by genetic, as opposed to clinical methods. The incremental cost per life year saved was €14 397 for the cascade genetic compared with the cascade clinical approach. Genetic diagnostic strategies are more likely to be cost-effective than clinical tests alone. The costs for cascade molecular genetic testing were slightly higher than clinical testing in the short run, but this was largely because the genetic approach is more effective and identifies more individuals at risk. Conclusion The use of molecular genetic information in the diagnosis and management of HCM is a cost-effective approach to the primary prevention of SCD in these patients.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>20299350</pmid><doi>10.1093/eurheartj/ehq067</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0195-668X |
ispartof | European heart journal, 2010-04, Vol.31 (8), p.926-935 |
issn | 0195-668X 1522-9645 |
language | eng |
recordid | cdi_proquest_miscellaneous_733887424 |
source | Oxford Journals Online |
subjects | Adolescent Adult Aged Biological and medical sciences Cardiology. Vascular system Cardiomyopathy, Hypertrophic, Familial - diagnosis Cardiomyopathy, Hypertrophic, Familial - economics Cardiomyopathy, Hypertrophic, Familial - genetics Child Cost-Benefit Analysis Cost-effectiveness analysis Death, Sudden, Cardiac - prevention & control Decision Trees Forecasting Genetic Testing - economics Genetic Testing - standards Genetics Heart Humans Hypertrophic cardiomyopathy Medical sciences Middle Aged Models, Economic Myocarditis. Cardiomyopathies Pedigree Risk Assessment Sensitivity and Specificity Young Adult |
title | DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T12%3A33%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=DNA%20testing%20for%20hypertrophic%20cardiomyopathy:%20a%20cost-effectiveness%20model&rft.jtitle=European%20heart%20journal&rft.au=Wordsworth,%20Sarah&rft.date=2010-04-01&rft.volume=31&rft.issue=8&rft.spage=926&rft.epage=935&rft.pages=926-935&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/eurheartj/ehq067&rft_dat=%3Cproquest_cross%3E733887424%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c474t-9919a39244060bdd7f1cf3e23f82b86c1aa0f590add78387858246902477d1ef3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=733887424&rft_id=info:pmid/20299350&rfr_iscdi=true |